Linked Life Data

20525485

Source:http://linkedlifedata.com/resource/pubmed/id/20525485

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-6-7
pubmed:abstractText
In February 2009, the European Medicines Agency suspended the marketing authorization for efalizumab after 3 confirmed cases of progressive multifocal leukoencephalopathy were reported. To assess the consequences of this decision, we performed a prospective follow-up study of patients in our department who were being treated with efalizumab at the time and compared clinical outcomes with data from the literature.
pubmed:language
spa
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1578-2190
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
101
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
421-7
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[Clinical outcomes in patients with psoriasis following discontinuation of efalizumab due to suspension of marketing authorization].
pubmed:affiliation
Hospital General Universitario Gregorio Marañón, Madrid, España. ofelia_baniandres@yahoo.es <ofelia_baniandres@yahoo.es>
pubmed:publicationType
Journal Article, English Abstract